Figure 4.

Efficacy of treatment on renal tumors of Tsc2^+/− mice.

Tsc2^+/− mice were treated from 12 months old for 2 months in 7 groups: vehicle (n = 17), 3-BrPA (n = 19), CB-839 (n = 20), rapamycin (n = 20), 3-BrPA+rapamycin (n = 18), CB-839 + rapamycin (n = 20), and 3-BrPA+CB-839 (n = 18). Three mice from the 3-BrPA group, three mice from the 3-BrPA+rapamycin group, and four mice from the 3-BrPA+CB-839 group were euthanized due to significant loss of body weight within the first month of treatment and excluded from further analysis in this study. Dosages are described in methods. After treatment, kidney sections were prepared for histological assessment of treatment efficacy. Left panel: comparison of total number and size (area) as well as cellular area of all lesions (cystic, papillary, and solid). Right panel: comparison of total number and size (area) as well as cellular area of solid carcinomas. Horizontal bars indicate a median. For detailed statistical analysis, see Supplementary Tables 1 and 2.